🔗 Share this article

Given that the United States proceeds with unprecedented adjustments to its vaccine recommendations, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots throughout the pandemic and has zeroed in on possible deaths following COVID-19 vaccination in her recent time at the FDA.

Proposed Overhauls to Pediatric Immunization Schedule

Health officials had intended to reveal radical changes to the pediatric vaccination calendar recently, bringing the US with the Danish immunization schedule, it is understood – a significant shift that would put the US at odds with much of the global community with insufficient data for public health gain. This reveal has been pushed back until the new year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to speak at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to run the division this calendar year.

A New Direction at the Regulatory Body

This interim role could signify a closer partnership between the drug and biologics branches as Dr. Høeg and Prasad solidify control at the agency – and it signals a greater focus upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for halting certain childhood shot schedules in the US in order to be more similar to Denmark, a society with nationalized medicine and a citizenry roughly the population of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on vaccines – typically the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Expertise

Høeg has no apparent track record in medication creation, regulation or administrative roles, which has been typical for past directors of the biologics center. She has worked at the FDA as a key advisor to the commissioner and CBER since spring.

“She appears not to have the requisite experience” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in managing a major agency. She has no expertise in industry regulation.”

Previous directors of the center would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, said Janet Woodcock. “Frankly, she doesn’t have the kind of background that previous people who headed CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she stated.

“Many people just pays attention on the innovative therapies, but the generic program clears numerous generic medications. There’s a biosimilars division, over-the-counter program and more, and all of those must be supervised,” Woodcock said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a significant management component to the position, which manages more than 5,000 employees. “It is a huge administrative position, if you execute it properly,” Woodcock said.

Official Statement and Disputed Policies

When asked about questions about Dr. Høeg's credentials and whether this selection represents increased cooperation among regulatory chiefs on vaccines, a representative responded that the “inquiries are based on flawed assumptions”.

“This background is consistent with the duties of her job,” the representative said, pointing to the months Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg takes over the agency head's controversial fast-track approval initiative, a controversial one-day drug-approval program that apparently worried her former heads. “By what process are these medications being chosen for this expedited pathway? Who is making the choices?” Howard asked. “There is a lot of lack of transparency happening at the agency right now.”

In general, he remarked, “the agency appears to be shifting towards more relaxed rules of most medications, with the exception of shots.”

Documented History on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if concerning, past, critics have noted. She released a analysis using unverified crowd-sourced reports to determine the frequency of heart inflammation following Covid vaccination. She advised the state of Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Part of her “wish list” for the incoming administration encompassed changing regulations for novel immunizations and discontinuing “optional” vaccines, she said post-election on a audio program. At the FDA, Dr. Høeg has reportedly floated the idea of barring adolescent males from obtaining Covid vaccines.

“She’s an all-around dogmatist who commences with her preconceived notions and tailors the evidence to fit the data in a very disingenuous, dishonest fashion,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg aligned with fellow contrarians, {like|